Atezolizumab in combination with intrathecal chemotherapy and radiation for treatment of isolated cerebral nervous system relapse in a patient with extranodal NK/T cell lymphoma: a case report

被引:0
作者
Amanda E. Lipsitt
Jaclyn Y. Hung
Anne-Marie Langevin
机构
[1] University of Texas Health San Antonio,Department of Pediatrics Hematology
来源
Journal of Medical Case Reports | / 15卷
关键词
NK/T cell lymphoma; Non-Hodgkin’s lymphoma; Epstein-Barr virus; Immune checkpoint inhibitor; Atezolizumab; CNS relapse;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 118 条
[1]  
Al-Hamadani M(2015)Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011 Am J Hematol. 90 790-795
[2]  
Habermann TM(2017)The diagnosis and management of NK/T-cell lymphomas J Hematol Oncol. 10 85-1684
[3]  
Cerhan JR(2019)Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma Leuk Lymphoma 60 1677-3790
[4]  
Macon WR(2005)Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type Blood 106 3785-566
[5]  
Maurer MJ(2016)Central nervous system involvement in T-cell lymphoma: a single center experience Acta Oncol. 55 561-41
[6]  
Go RS(2015)Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study Blood 126 36-593
[7]  
Tse E(2018)The risk of central nervous system relapses in patients with peripheral T-cell lymphoma PLoS One 13 e0191461-68
[8]  
Kwong YL(2002)Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy Leuk Lymphoma 43 587-3473
[9]  
Nevel KS(2018)Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma Eur J Cancer. 93 57-31
[10]  
Pentsova E(2013)PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies Clin Cancer Res 19 3462-2442